The Journal of infectious diseases · 2025
Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Клиническое исследование I фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eron Joseph J, Cook Paul P, Mehrotra Megha L, Huang Hailin, Caskey Marina, Crofoot Gordon E, Gorgos Linda, VanderVeen Laurie A, Zheng Yanan, Collins Sean E, Osiyemi Olayemi O, Brinson Cynthia, DeJesus Edwin
Аннотация
BACKGROUND: The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs.
METHODS: This was a pilot study within a proof-of-concept phase 1b study.
RESULTS: No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26.
CONCLUSIONS: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.
METHODS: This was a pilot study within a proof-of-concept phase 1b study.
RESULTS: No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26.
CONCLUSIONS: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.